Jonathan McNeill - 16 Sep 2026 Form 4 Insider Report for CRESCENT BIOPHARMA, INC. (CBIO)

Reporting relationship: President and COO
Issuer ticker: CBIO
Reported as of: 16 Sep 2026
Net transaction value: -$77,235
SEC form: 4
Accepted by SEC: 18 Sep 2026, 16:01:44 UTC
Prior SEC filing: 23 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Barbara Bispham Hale, as attorney-in-fact for Jonathan McNeill

Key filing fact

Jonathan McNeill filed Form 4 for CRESCENT BIOPHARMA, INC. (CBIO) on 18 Sep 2026.

Key facts

This page summarizes Jonathan McNeill's Form 4 filing for CRESCENT BIOPHARMA, INC. (CBIO).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 18 Sep 2026, 16:01.

Change

Previous filing in this sequence was filed on 23 Jun 2026.
Current net transaction value: -$77,235.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001824673 Primary reporting owner

McNeill Jonathan

Relationship: President and COO
Address: C/O CRESCENT BIOPHARMA, INC., 300 FIFTH AVENUE, WALTHAM
Signature: /s/ Barbara Bispham Hale, as attorney-in-fact for Jonathan McNeill
Signature date: 18 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CBIO transaction

Ordinary Shares

Sale

Transaction value: $13,085
Shares: -731
Change %: -0.53%
Price: $17.90
Shares after: 138,427
Date: 16 Sep 2026
Ownership: Direct
Footnotes: F1, F2

CBIO transaction

Ordinary Shares

Sale

Transaction value: $64,150
Shares: -3,839
Change %: -2.8%
Price: $16.71
Shares after: 134,588
Date: 18 Sep 2026
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units granted to the Reporting Person on December 15, 2025 and March 17, 2025. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 instruction adopted by the reporting person on February 25, 2026, solely with the intent to cover taxes in connection with the vesting of the restricted stock units.

Footnote F2

The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $17.10 to $19.17 on September 16, 2026 and from $16.15 to $17.23 on September 18, 2026, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.

SEC remarks

Exhibit 24 - Power of Attorney